About

PhaseRx is developing a portfolio of mRNA products to treat children with life-threatening inherited liver diseases, and expects to achieve clinical proof of concept in patients with an approvable end point in 2018.

Read More

Email Alerts

Email Address: *
Mailing Lists *



 
Enter the code shown above.